Infertility is medically described as the inability of a woman to become pregnant after nine months of unprotected sexual intercourse (or without using any birth control pills). According to the NHS, U.K., around 1 in 7 couples have problems conceiving, which is around 4 million people. A common cause behind infertility among women is problems with ovulation. According to several medical practitioners, lack of ovulation can result from polycystic ovary syndrome, thyroid problems (both overactive thyroid glands and underactive thyroid glands hamper ovulation), and premature ovarian failure in women. In addition, pelvic or cervical surgery, thinner cervical mucus, fibroids (non-cancerous growth around wombs), and endometriosis can be the reasons for infertility among women. Furthermore, overuse of non-steroidal anti-inflammatory drugs, chemotherapy, neuroleptic medicines, spironolactone, and illegal drugs such as marijuana and cocaine may cause problems in ovulation among women.
Infertility among men is caused by poor quality of sperms and semen, injury to the testicles (caused by testicular cancer, testicular surgery, etc.), ejaculation disorders, and overuse of medications such as sulfasalazine and anabolic steroids. Common diagnostic examinations include blood test, ultrasound scan, chlamydia test, and laparoscopy (semen analysis for infertility testing among men).
The global infertility drugs market is primarily driven by a rise in cases of infertility among couples across the world, rise in rate of diagnosis and treatment of infertility, and development in health care infrastructure. However, stringent regulatory conditions and intellectual property rights law for infertility drugs are anticipated to hamper the growth of global infertility drugs market. Nevertheless, on-going clinical trials on infertility drugs, increase in research and development expenditure, and major mergers and acquisitions among key companies are projected to provide the global infertility drugs market attractive opportunities in the coming years.
The global infertility drugs market can be segmented based on drug class, end-user, drug type, distribution channel, and region. In terms of drug class, the market can be classified into ovulatory stimulants, selective estrogen receptor modulators (SERMs), biguanides, dopamine agonists, tricyclic antidepressants, and others. Based on end-user, the global infertility drugs market can be classified into male and female. In terms drug type, the global infertility drugs market can be segmented into branded and generic. Based on distribution channel, the global infertility drugs market can be divided into hospital pharmacies, retail pharmacies and drug stores, and others.
In terms of region, the global infertility drugs market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America held a leading share of the global infertility drugs market in 2017, owing to a highly developed pharmaceutical industry, high rate of diagnosis and treatment of infertility, well-established health care infrastructure, and presence of major players in the region. In Europe, Germany, France, and the U.K. accounted for a major share of the infertility drugs market in 2017.The market in Italy and Spain is expected to expand at a significant growth rate during the forecast period. Highly developed health care industry, high rate of diagnosis and treatment of infertility, and participation of small companies in the market are the key factors that contributed to the significant market share of Germany, France, and the U.K. in 2017.
In Asia, China and Japan held a dominant share of the infertility drugs market in 2017. The infertility drugs market in India is estimated to expand at a significant CAGR in the near future, owing to the developing healthcare industry, presence of well-established domestic players, and intense competition between domestic and international players in the country. An underdeveloped health care industry and lack of awareness about infertility drugs are likely to hamper the infertility drugs market in Latin America and Middle East & Africa during the forecast period.
Key companies operating in the infertility drugs market include Pfizer, Takeda Pharmaceutical Company Limited, F. Hoffmann-La Roche Ltd, Merck, and Eli Lilly.
This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.
Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:
- Customer Experience Maps
- Insights and Tools based on data-driven research
- Actionable Results to meet all the business priorities
- Strategic Frameworks to boost the growth journey
The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.
The following regional segments are covered comprehensively:
- North America
- Asia Pacific
- Latin America
- The Middle East and Africa
The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.
Below is a snapshot of these quadrants.
1. Customer Experience Map
The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.
2. Insights and Tools
The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.
3. Actionable Results
The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.
4. Strategic Frameworks
The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.
The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:
1. What can be the best investment choices for venturing into new product and service lines?
2. What value propositions should businesses aim at while making new research and development funding?
3. Which regulations will be most helpful for stakeholders to boost their supply chain network?
4. Which regions might see the demand maturing in certain segments in near future?
5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?
6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?
7. Which government regulations might challenge the status of key regional markets?
8. How will the emerging political and economic scenario affect opportunities in key growth areas?
9. What are some of the value-grab opportunities in various segments?
10. What will be the barrier to entry for new players in the market?
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.